The -759C/T polymorphism of the 5-HT2C receptor is associated with type 2 diabetes in male and female Caucasians

Pharmacogenetics and Genomics

Volumn 18, Issue 2, 2008, Pages 153-159

  Iordanidou, Maria ^a   Tavridou, Anna ^a   Vasiliadis, Michalis V ^c   Arvanitidis, Kostas I ^a   Petridis, John ^a   Christakidis, Dimitrios ^b   Vargemezis, Vassilios ^b   Bougioukas, George ^b   Manolopoulos, Vangelis G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Academic General Hospital Alexandroupolis   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

759C T polymorphism; 5 HT2C receptor gene; Obesity; Serotonin; Sex; Type 2 diabetes mellitus

Indexed keywords

GENOMIC DNA; SEROTONIN 2C RECEPTOR;

AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; SEX DIFFERENCE;

AGED; BASE SEQUENCE; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 38149074099     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f4ae93     Document Type: Article

References (35)

1. Kahn SE, Hull RL, Utzscheider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-846.
2. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42:1663-1672.
3. Kahn SE. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86:4047-4058.
4. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-643.
5. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes mellitus. Diabetes Care 1999; 22:1266-1272.
6. Miller KJ. Serotonin 5-HT receptor agonists: potential for the treatment of obesity. Mol Interv 2005; 5:282-291.
7. 2C receptor. Eur J Pharmacol 1994; 269:339-348.
8. 2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res 2007; 1149:14-17.
9. 2C receptor polymorphism separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005; 15:143-151.
10. 2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7:670-671.
11. 2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43:373-376.
12. 2C receptor gene with antipsychotic-induced weight gain. Am J Psych 2005; 163:613-615.
13. Meyer J, Saam W, Mossner R, Cangir O, Ortega GR, Tatschner T. Evolutionary conserved microsatellites in the promoter region of the 5-hydroxytryptamine receptor 2C gene (HTR2C) are not associated with bipolar disorder in females. J Neural Transm 2002; 109:939-946.
14. 2C receptor gene. Neuroreport 1995; 7:169-172.
15. 2A receptor gene. Behav Brain Res 1996; 73:59-62.
16. Parkinson WL, Weingarten HP. Dissociative analysis of ventromedial hypothalamic obesity syndrome. Am J Physiol 1990; 259:829-835.
17. 2C receptor promoter polymorphism (HTR2C-759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. Am J Med Genet 2004; 126:124-127.
18. Whitley E, Ball J. Statistics review 4: sample size calculations. Crit Care 2002; 6:335-341.
19. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996; 143:228-239.
20. 2C receptor -759C/T polymorphism. Am J Med Genet, B Neuropsychiatr Genet 2005; 133:97-100.
21. 2C receptor and olanzapine. Am J Med Genetics Part B (Neuropsychiatric Genetics) 2005; 133:97-100.
22. 2C receptor gene polymorphism. Lancet 2002; 359:2086-2087.
23. Tsai SJ, Hong CJ, Yu YW, Lin CH. -759C/T genetic variation of 5-HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360:1790.
24. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360:1790-1791.
25. 2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004; 14:139-142.
26. Mulder H, Franke B, Aart van der - Beek van der A, Arends J, Wilmink FW, Scheffer H. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27:338-343.
27. 2C receptor and antipsychotic-induced weight gain - mechanisms and genetics. Journal of Psychopharmacology 2006; 20:15-18.
28. Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007; 9:1-24.
29. Peschke E, Peschke D, Hammer T, Csernus V. Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro. J Pineal Res 1997; 23:156-163.
30. 2C receptor gene. Nat Med 1998; 4:1152-1156.
31. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psych 2005; 62:19-28.
32. Chiu CC, Chen KP, Liu HC, Lu ML. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharm 2006; 26:504-507.
33. Gury C. Schizophrenia, diabetes mellitus and antipsychotics. Encephale 2004; 30:382-391.
34. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psych 2004; 18:36-46.
35. Gilles M, Wilke A, Kopf D, Nonell A, Lehnert H, Deuschle M. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom Med 2005; 67:748-751.